S&P 500
(0.25%) 5 321.41 points
Dow Jones
(0.17%) 39 873 points
Nasdaq
(0.22%) 16 833 points
Oil
(-0.93%) $79.06
Gas
(-3.20%) $2.66
Gold
(-0.56%) $2 424.90
Silver
(-0.62%) $32.23
Platinum
(-0.07%) $1 063.00
USD/EUR
(0.05%) $0.921
USD/NOK
(-0.21%) $10.67
USD/GBP
(-0.04%) $0.787
USD/RUB
(-0.51%) $90.21

Realtime updates for Fulcrum Therapeutics Inc [FULC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
66.67%
return 19.23%
SELL
40.00%
return 9.20%
Last Updated21 May 2024 @ 16:00

-0.78% $ 7.64

SELL 139776 min ago

@ $8.91

Issued: 14 Feb 2024 @ 14:26


Return: -14.25%


Previous signal: Feb 13 - 15:22


Previous signal: Buy


Return: -1.22 %

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 16:00):
Profile picture for Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States...

Stats
Today's Volume 464 521
Average Volume 628 235
Market Cap 474.85M
EPS $0 ( 2024-05-20 )
Next earnings date ( $-0.0600 ) 2024-08-01
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.81
ATR14 $0.0100 (0.13%)
Insider Trading
Date Person Action Amount type
2024-05-07 Tourangeau Greg Sell 236 Common Stock
2024-03-18 Horn Patrick Taylor Buy 400 000 Stock Option (right to buy)
2024-03-18 Horn Patrick Taylor Sell 0 No securities are beneficially owned
2024-03-08 Tourangeau Greg Sell 4 884 Common Stock
2024-03-04 Sapir Alex Buy 43 360 Common Stock
INSIDER POWER
20.60
Last 98 transactions
Buy: 8 691 029 | Sell: 9 091 582

Volume Correlation

Long: 0.07 (neutral)
Short: -0.55 (weak negative)
Signal:(56.086) Neutral

Fulcrum Therapeutics Inc Correlation

10 Most Positive Correlations
GRPN0.894
RLMD0.892
CSX0.885
NRBO0.884
MORF0.882
ORMP0.882
ALLO0.88
CRSP0.868
SGMO0.864
PTH0.86
10 Most Negative Correlations
RGLD-0.835
SGLY-0.807
STKS-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fulcrum Therapeutics Inc Correlation - Currency/Commodity

The country flag -0.46
( neutral )
The country flag -0.26
( neutral )
The country flag 0.00
( neutral )
The country flag 0.18
( neutral )
The country flag -0.45
( neutral )
The country flag 0.37
( neutral )

Fulcrum Therapeutics Inc Financials

Annual 2023
Revenue: $2.81M
Gross Profit: $633 000 (22.57 %)
EPS: $-1.590
FY 2023
Revenue: $2.81M
Gross Profit: $633 000 (22.57 %)
EPS: $-1.590
FY 2022
Revenue: $6.34M
Gross Profit: $3.93M (61.94 %)
EPS: $-2.35
FY 2021
Revenue: $19.16M
Gross Profit: $19.16M (100.00 %)
EPS: $-2.29

Financial Reports:

No articles found.

Fulcrum Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators